The MAPK pathway sustains cyclin D1 levels, and we find in the context of therapy naïve ALM cells, elevated MAPK activity promotes ALM addiction to cyclin D1, which can be overcome with use of the clinical MEK inhibitor trametinib, an ERK inhibitor, or genetic silencing of cyclin D1. Here, MAP2K7 is linked to acral lentiginous melanoma.